A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab

Abstract

Background:

Tissue damage in both multiple sclerosis (MS) lesions and normal-appearing white matter (NAWM) are important contributors to disability and progression. Specific aspects of MS pathology can be measured using advanced imaging. Alemtuzumab is a humanised monoclonal antibody targeting CD52 developed for MS treatment.

Objective:

To investigate changes over 2 years of advanced magnetic resonance (MR) metrics in lesions and NAWM of MS patients treated with alemtuzumab.

Methods:

A total of 42 relapsing–remitting alemtuzumab-treated MS subjects were scanned for 2 years at 3 T. T₁ relaxation, T₂ relaxation, diffusion tensor, MR spectroscopy and volumetric sequences were performed. Mean T₁ and myelin water fraction (MWF) were determined for stable lesions, new lesions and NAWM. Fractional anisotropy was calculated for the corpus callosum (CC) and N-acetylaspartate (NAA) concentration was determined from a large NAWM voxel. Brain parenchymal fraction (BPF), cortical thickness and CC area were also calculated.

Results:

No change in any MR measurement was found in lesions or NAWM over 24 months. BPF, cortical thickness and CC area all showed decreases in the first year followed by stability in the second year.

Conclusion:

Advanced MR biomarkers of myelin (MWF) and neuron/axons (NAA) show no change in NAWM over 24 months in alemtuzumab-treated MS participants.

Keywords

Multiple sclerosis MRI myelin water alemtuzumab longitudinal multicentre

Get full access to this article

View all access options for this article.

References

Allen

McKeown

SR.

A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41(1): 81–91.

Fatouros

Marmarou

Kraft

et al . In vivo brain water determination by T1 measurements: Effect of total water content, hydration fraction, and field strength. Magn Reson Med 1991; 17(2): 402–413. DOI: 10.1002/mrm.1910170212.

MacKay

Whittall

Adler

et al . In vivo visualization of myelin water in brain by magnetic resonance. Magn Reson Med 1994; 31(6): 673–677.

Laule

Kozlowski

Leung

et al . Myelin water imaging of multiple sclerosis at 7 T: Correlations with histopathology. Neuroimage 2008; 40(4): 1575–1580. DOI: 10.1016/j.neuroimage.2007.12.008.

Laule

Vavasour

Moore

GRW

et al . Water content and myelin water fraction in multiple sclerosis: A T2 relaxation study. J Neurol 2004; 251(3): 284–293. DOI: 10.1007/s00415-004-0306-6.

Inglese

Bester

Diffusion imaging in multiple sclerosis: Research and clinical implications. NMR Biomed 2010; 23(7): 865–872. DOI: 10.1002/nbm.1515.

Bjartmar

Battistuta

Terada

et al . N-acetylaspartate is an axon-specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002; 51(1): 51–58.

Gonen

Moriarty

BSY

et al . Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: Evidence for different clinical cohorts initial observations. Radiology 2002; 225(1): 261–268. DOI: 10.1148/radiol.2243011260.

Vavasour

Huijskens

DKB

et al . Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter. Mult Scler 2018; 24: 1557–1568.

10.

Parry

Clare

Jenkinson

et al . MRI brain T1 relaxation time changes in MS patients increase over time in both the white matter and the cortex. J Neuroimaging 2003; 13(3): 234–239.

11.

Bellmann-Strobl

Stiepani

Wuerfel

et al . MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: A combined cross-sectional and longitudinal study. Eur Radiol 2009; 19(8): 2066–2074.

12.

Tiberio

Chard

Altmann

et al . Metabolite changes in early relapsing-remitting multiple sclerosis: A two year follow-up study. J Neurol 2006; 253(2): 224–230.

13.

Harrison

Caffo

Shiee

et al . Longitudinal changes in diffusion tensor–based quantitative MRI in multiple sclerosis. Neurology 2011; 76(2): 179–186. DOI: 10.1212/WNL.0b013e318206ca61.

14.

Havrdova

Horakova

Kovarova

Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8(1): 31–45. DOI: 10.1177/1756285614563522.

15.

Cohen

Coles

Arnold

et al . Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012; 380(9856): 1819–1828. DOI: 10.1016/S0140-6736(12)61769-3.

16.

Coles

Twyman

Arnold

et al . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380(9856): 1829–1839. DOI: 10.1016/S0140-6736(12)61768-1.

17.

Prasloski

Madler

Xiang

Q-S

et al . Applications of stimulated echo correction to multicomponent T2 analysis. Magn Reson Med 2012; 67(6): 1803–1814. DOI: 10.1002/mrm.23157.

18.

Yoo

Prasloski

Vavasour

et al . Fast computation of myelin maps from MRI T2 relaxation data using multicore CPU and graphics card parallelization. J Magn Reson Imaging 2015; 41(3): 700–707. DOI: 10.1002/jmri.24604.

19.

Jenkinson

Bannister

Brady

et al . Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002; 17(2): 825–841.

20.

McAusland

Tam

Wong

et al . Optimizing the use of radiologist seed points for improved multiple sclerosis lesion segmentation. IEEE Trans Biomed Eng 2010; 57(11): 2689–2698.

21.

Zhang

Brady

Smith

Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001; 20(1): 45–57. DOI: 10.1109/42.906424.

22.

MacMillan

Tam

Zhao

et al . Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years. Mult Scler J 2016; 22: 112–116.

23.

Jones

Zhao

et al . Atrophy measurements in multiple sclerosis. In: Proceedings of the international society for magnetic resonance in medicine, Glasgow, 21–27 April 2001, p. 1414. Concord, CA: ISMRM.

24.

Garg

Tang

Traboulsee

et al . A sensitive and efficient method for measuring change in cortical thickness using fuzzy correspondence in Alzheimer’s disease. In: Proceedings of the international conference on image processing (ICIP), Quebec City, QC, Canada, 27–30 September 2015, pp. 3014–3018. New York: IEEE.

25.

Tang

LYW

Hamarneh

DKB

et al . Corpus callosum segmentation in MS studies using normal atlases and optimal hybridization of extrinsic and intrinsic image cues. In: Proceedings of medical image computing and computer assisted intervention (MICCAI) Part III, Munich, 5–9 October 2015, pp. 123–131. London: Springer.

26.

Richert

Howard

Frank

et al . Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis. Neurology 2006; 66(4): 551–556. DOI: 10.1212/01.wnl.0000197982.78063.06.

27.

Vavasour

Laule

DKB

et al . Longitudinal changes in myelin water fraction in two MS patients with active disease. J Neurol Sci 2009; 276(1–2): 49–53. DOI: 10.1016/j.jns.2008.08.022.

28.

van Walderveen

MAA

van Schijndel

Pouwels

PJW

et al . Multislice T1 relaxation time measurements in the brain using IR-EPI: Reproducibility, normal values, and histogram analysis in patients with multiple sclerosis. J Magn Reson Imaging 2003; 18(6): 656–664.

29.

Wiebenga

Schoonheim

Hulst

et al . White matter diffusion changes during the first year of natalizumab Treatment in relapsing-remitting multiple sclerosis. AJNR 2016; 37(6): 1030–1037. DOI: 10.3174/ajnr.A4690.

30.

Rashid

Hadjiprocopis

Davies

et al . Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging. J Neurol 2008; 255(3): 390–397. DOI: 10.1007/s00415-008-0678-0.

31.

Razmjou

Bao

Yarraguntla

et al . Myelin repair and improved axonal integrity over time in relapsing remitting multiple sclerosis: Comparative analysis of fingolimod, natalizumab and glatitamer acetate (P6.378). Neurology 2017; 88(Suppl. 16).

32.

Filippi

Rocca

Pagani

et al . Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2014; 85(8): 851–858.

33.

Button

Altmann

Tozer

et al . Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Mult Scler 2013; 19(2): 241–244.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.61 MB